APOE4 alters the regional levels of numerous neuroimaging biomarkers across the Alzheimer's disease continuum

These observations of pathological heterogeneity between APOE4 carriers vs. non-carriers reveal significant differences in disease pathogenesis between these two groups, which may have important implications with regard to the diagnosis and treatment of AD in different at-risk populations.